Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...

ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...